Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.
Cybersecurity software maker Tenable (NASDAQ:TENB) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 10.7% year on year to $239.1 million. The company expects next quarter’s revenue to be around $242 million, close to analysts’ estimates. Its non-GAAP profit of $0.36 per share was 27.5% above analysts’ consensus estimates.
Data storage manufacturer Seagate (NASDAQ:STX) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 30.5% year on year to $2.16 billion. On the other hand, next quarter’s revenue guidance of $2.4 billion was less impressive, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $1.90 per share was 9.3% above analysts’ consensus estimates.
Online travel agency Booking Holdings (NASDAQ:BKNG) announced better-than-expected revenue in Q1 CY2025, with sales up 7.9% year on year to $4.76 billion. Its non-GAAP profit of $24.81 per share was 41.2% above analysts’ consensus estimates.
Recreational vehicle (RV) and boat retailer Camping World (NYSE:CWH) fell short of the market’s revenue expectations in Q1 CY2025 as sales rose 3.6% year on year to $1.41 billion. Its non-GAAP loss of $0.15 per share was 26.5% above analysts’ consensus estimates.
Flow control equipment manufacturer Flowserve (NYSE:FLS) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $1.14 billion. Its non-GAAP profit of $0.72 per share was 19.6% above analysts’ consensus estimates.
Power conversion and control solutions provider Vicor Corporation (NASDAQ:VICR) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 12% year on year to $93.97 million. Its non-GAAP profit of $0.14 per share was 52.5% below analysts’ consensus estimates.
Data analytics and digital solutions company ExlService Holdings (NASDAQ:EXLS) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 14.8% year on year to $501 million. The company expects the full year’s revenue to be around $2.05 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 8.9% above analysts’ consensus estimates.
Hotel and casino entertainment company Caesars Entertainment (NASDAQ:CZR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $2.79 billion. Its non-GAAP loss of $0.54 per share was significantly below analysts’ consensus estimates.
Communications chips maker Qorvo (NASDAQ: QRVO) announced better-than-expected revenue in Q1 CY2025, but sales fell by 7.6% year on year to $869.5 million. The company expects next quarter’s revenue to be around $775 million, close to analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.3% above analysts’ consensus estimates.
HR outsourcing provider Insperity (NYSE:NSP) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 3.4% year on year to $1.86 billion. Its non-GAAP profit of $1.56 per share was 23% below analysts’ consensus estimates.
Athletic apparel company Under Armour (NYSE:UAA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 11.4% year on year to $1.18 billion. On the other hand, next quarter’s revenue guidance of $1.13 billion was less impressive, coming in 3.4% below analysts’ estimates. Its non-GAAP loss of $0.08 per share was in line with analysts’ consensus estimates.
Bernstein bullish on Coinbase after S&P 500 inclusion, projecting $16B in potential inflows from passive & active investment. Also first crypto firm to join benchmark index.
Trucking company PACCAR (NASDAQ:PCAR) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 16% year on year to $6.91 billion. Its non-GAAP profit of $1.46 per share was 7.5% below analysts’ consensus estimates.
Data backup provider Commvault (NASDAQ:CVLT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 23.2% year on year to $275 million. The company expects next quarter’s revenue to be around $268 million, close to analysts’ estimates. Its non-GAAP profit of $1.03 per share was 10.7% above analysts’ consensus estimates.
Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.6% year on year to $359.3 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.
Glass and electronic component manufacturer Corning (NYSE:GLW) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 16% year on year to $3.45 billion. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $3.85 billion at the midpoint, or 3.5% above analysts’ estimates. Its non-GAAP profit of $0.54 per share was 5.3% above analysts’ consensus estimates.
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company’s full-year revenue guidance of $753 million at the midpoint came in 2% above analysts’ estimates. Its non-GAAP loss of $0 per share was in line with analysts’ consensus estimates.
Paint and coating manufacturer Sherwin-Williams (NYSE:SHW) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 1.1% year on year to $5.31 billion. Its non-GAAP profit of $2.25 per share was 4.1% above analysts’ consensus estimates.
Construction equipment company Astec (NASDAQ:ASTE) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 6.5% year on year to $329.4 million. Its non-GAAP profit of $0.88 per share was 91.3% above analysts’ consensus estimates.
Environmental solutions provider CECO Environmental (NASDAQ:CECO) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 39.9% year on year to $176.7 million. The company’s full-year revenue guidance of $725 million at the midpoint came in 3.5% above analysts’ estimates. Its non-GAAP profit of $0.10 per share was 12.2% above analysts’ consensus estimates.
E-commerce and gaming company Sea (NYSE:SE) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 29.6% year on year to $4.84 billion. Its GAAP profit of $0.65 per share was 7.1% above analysts’ consensus estimates.
USD/CHF has a pronounced seasonal tendency for weakness through late spring and summer, a pattern that could come into sharper focus as the pair approaches key resistance.
Affordable single-family home construction company LGI Homes (NASDAQ:LGIH) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 10.1% year on year to $351.4 million. Its non-GAAP profit of $0.17 per share was 73.1% below analysts’ consensus estimates.
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit of $1.16 per share was 10.6% above analysts’ consensus estimates.
Packaged foods company Kraft Heinz (NASDAQ:KHC) met Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 6.4% year on year to $6 billion. Its non-GAAP profit of $0.62 per share was 3% above analysts’ consensus estimates.
China firmly rejected responsibility for the U.S. fentanyl crisis on Tuesday, calling Washington's punitive tariffs "unreasonable" even as broader trade tensions between the world's two largest economies show signs of easing.
Tobacco company Altria (NYSE:MO) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 4.2% year on year to $4.52 billion. Its non-GAAP profit of $1.23 per share was 3.5% above analysts’ consensus estimates.
Real estate services firm Cushman & Wakefield (NYSE:CWK) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 4.6% year on year to $2.28 billion. Its non-GAAP profit of $0.09 per share was significantly above analysts’ consensus estimates.
Pharma stocks saw a relief rally, with Sun Pharma and Dr. Reddy’s gaining over 1% each, after U.S. President Donald Trump’s executive order on drug pricing was considered less stringent than anticipated.
